Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.
Van Sanden S, Pisini M, Duchesne I, Mehnert A, Belsey J. Van Sanden S, et al. Curr Med Res Opin. 2016;32(1):147-54. doi: 10.1185/03007995.2015.1106934. Epub 2015 Oct 29. Curr Med Res Opin. 2016. PMID: 26455472
Mixed Treatment Comparisons to Compare Simeprevir with Boceprevir and Telaprevir in Combination with Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected with Genotype 1 Hepatitis C Virus (Hcv).
Taieb V, Pacou M, Van Sanden S, Sbarigia U, Mehnert A, Duchesne I. Taieb V, et al. Among authors: van sanden s. Value Health. 2014 Nov;17(7):A665. doi: 10.1016/j.jval.2014.08.2450. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202427 Free article. No abstract available.
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Martin T, et al. Among authors: van sanden s. Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23. Curr Med Res Opin. 2021. PMID: 34256668 Clinical Trial.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Roccia T, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Pacaud L, Garrett A, Bartlett M, Haltner A, Van Sanden S, Diels J, Valluri S, Samjoo IA. Martin T, et al. Among authors: van sanden s. Curr Med Res Opin. 2023 Jan;39(1):81-89. doi: 10.1080/03007995.2022.2139052. Epub 2022 Nov 15. Curr Med Res Opin. 2023. PMID: 36271807
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA. Chowdhury S, et al. Among authors: van sanden s. Adv Ther. 2020 Jan;37(1):501-511. doi: 10.1007/s12325-019-01156-5. Epub 2019 Dec 7. Adv Ther. 2020. PMID: 31813086 Free PMC article.
41 results